[PDF] Top 20 Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting

... maximum nausea 25 mm on a 100 mm VAS); complete response at best (no emesis, no rescue therapy, maximum nausea 25 mm on a 100 mm VAS); and incomplete response (complement of the preced- ing states: some ... See full document

... II evidence and demonstrate that addition of aprepitant to a standard antiemetic regimen of a serotonin antagonist plus a corticosteroid results in significantly greater control of emesis, particularly in ... See full document

... of chemotherapy, which was in contrast to the other antagonist cohorts, where MEC was the predominant regimen (range, ...received aprepitant at cycle ... See full document

... of chemotherapy-induced nausea and vomiting (CINV) is a crucial factor in ensuring that patients undergoing cancer chemotherapy can get the full benefit of ...antagonist ... See full document

... oral aprepitant, 32 mg IV ondansetron, and 12 mg oral dexamethasone were given to subjects on day 1 followed by 80 mg oral aprepitant and 4 mg oral dexamethasone on days ...the prevention of both ... See full document

... antagonist, aprepitant, was approved in 2003, followed by fosaprepitant (a prodrug of aprepitant that is administered intravenously) in 2008 and netupitant (administered as a fixed oral combination ... See full document

... direct evidence of the efficacy of aprepitant in this context is ...of aprepitant (potential for drug interaction with chemotherapy and altered chemotherapy exposure) and benefits (CINV ... See full document

... treatment. Fosaprepitant has been approved for the prevention and treat- ment of CINV caused by moderately and highly emetogenic ...to aprepitant in the management of ... See full document

... postoperative nausea and vomiting (PONV) for a substantial number of ...preventing chemotherapy induced nausea and vomiting ...adding aprepitant to our current ... See full document

... in chemotherapy-induced nausea and vomiting, in patients receiving moderately and highly emetogenic chemotherapy, compared with 2 mg of oral ...emesis induced by ... See full document

... antagonist aprepitant for the prevention of chemotherapy-induced nau- sea and vomiting: a multinational, randomized, double-blind, placebo- controlled trial in patients receiving ... See full document

... after chemotherapy include a number of structures in the temporal lobe, such as the ...23,24 Evidence for this pathway is less well established than for other proposed sites of chemotherapeutic ... See full document

... for vomiting times and nausea ...data, nausea severity and times of vomiting were ...of chemotherapy was every three weeks and each course took four days and administered ...of ... See full document

... Postoperative nausea and vomiting (PONV) is a very common complication after anaesthesia and surgery ...postoperative nausea and vomiting, when no prophylactic antiemetic is given [7, ... See full document

... anticipatory nausea (AN; Limebeer et ...a nausea-inducing drug, as the unconditioned stimulus, and a distinctive context as the conditioned ...toxin-induced nausea with the context in which ... See full document

... receiving chemotherapy is nausea and vomiting ...starting chemotherapy (acute), or persist for 24 hours or more or begin 24 hours afterchemotherapy (delayed) or before patients actually ... See full document

... comparing nausea level before chemotherapy and at 2, 6 and 12 hours after chemotherapy in the patients of intervention and control groups, the results in the tables 4-6 show that the two groups have ... See full document

... after chemotherapy and 345 patients who used oral THC ...from nausea and vomiting, and 76%–88% of those who ingested the oral THC capsules experienced ... See full document

... cisplatin-based chemotherapy for testicular cancer, received 2 mg nabilone or 10 mg prochlorperazine every 6 hours as needed during chemotherapy cycle one and crossed over to the second drug during cycle ... See full document

... effective prevention of CINV and simplifying management, especially in patients with comorbidities who are receiving multiple therapies or patients who are older and/or have cognitive ... See full document